Induction of Labor with Oral Misoprostol – Effectiveness and Safety of Low-dose vs. High-dose Regimens

Abstract

Background

Before the market launch of low-dose misoprostol (LDM) in the form of 25 µg tablets, high-dose misoprostol (HDM) was used off-label for labor induction in Germany. The differences between the effectiveness and safety of both dosage forms were investigated.

Method

This retrospective cohort study included all pregnant women who were induced with misoprostol between 2019 and 2023. Until September 2021, misoprostol was available in the form of a 200 µg tablet which was divided manually and administered orally at an initial dose of 50 µg, followed by 100 µg every four hours. This was compared with the current administration regimen of an initial dose of 25 µg followed by 50 µg in terms of vaginal birth rate, duration of induction, and maternal and neonatal outcomes.

Results

A total of 1941 patients were analyzed; 1397 received HDM and 544 received LDM. Vaginal delivery was achieved with equal frequency (87% HDM vs. 88% LDM, p = 0.95). The duration of induction was shorter in the HDM group (20.7 hours vs. LDM 22.7 hours, p = 0.028), and opioid requirements were higher (HDM 74% vs. LDM 69%, p = 0.036). Maternal complications and neonatal outcomes did not differ. Regression analysis found that high BMI was an independent factor for a failed first induction attempt (B 0.002, SEM 0.0004, p < 0.001).

Conclusion

Both dosing regimens achieved high vaginal birth rates with comparable safety. Inductions with HDM were two hours shorter but were associated with higher opioid use.

Keywords

induction of labor - misoprostol - normal birth

Publication History

Received: 20 May 2025

Accepted after revision: 27 September 2025

Article published online:
04 November 2025

• References/Literatur

• 1 Institut für Qualitätssicherung und Transparenz im Gesundheitswesen. Bundesauswertung Perinatalmedizin: Geburtshilfe. Erfassungsjahr 2021. Accessed April 10, 2025 at: https://iqtig.org/downloads/auswertung/2021/pmgebh/DeQS_PM-GEBH_2021_BUAW_V01_2022-06-30.pdf
• 2 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG). S2k-Leitlinie Geburtseinleitung. Induction of labour. Guideline of the German Society of Gynecology and Obstetrics (S2k, AWMF Registry No. 015–088). 2020 Accessed April 10, 2025 at: https://register.awmf.org/de/leitlinien/detail/015-088
• 3 Bishop EH. Pelvic scoring for elective induction. 50 Studies Every Obstetrician-Gynecologist Should Know. Obstet Gynecol 1964; 24: 266-268
• 4 Crane JM. Factors predicting labor induction success: a critical analysis. Clin Obstet Gynecol 2006; 49: 573-584
• 5 Levine LD. Cervical ripening: Why we do what we do. Semin Perinatol 2020; 44: 151216
• 6 Chen W, Xue J, Peprah MK. et al. A systematic review and network meta-analysis comparing the use of Foley catheters, misoprostol, and dinoprostone for cervical ripening in the induction of labour. BJOG 2016; 123: 346-354
• 7 World Health Organization. WHO Model List of Essential Medicines – 23rd List. 2023 Accessed August 17, 2025 at: https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1
• 8 Pfizer Ltd.. New Zealand Data Sheet: Cytotec 200 microgram tablets. New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE). 2019 Accessed April 10, 2025 at: https://www.medsafe.govt.nz/profs/Datasheet/c/Cytotectab.pdf
• 9 Tang J, Kapp N, Dragoman M. et al. WHO recommendations for misoprostol use for obstetric and gynecologic indications. Int J Gynaecol Obstet 2013; 121: 186-189
• 10 Alfirevic Z, Aflaifel N, Weeks A. Oral misoprostol for induction of labour. Cochrane Database Syst Rev 2014; (06) CD001338
• 11 Goecke T, Voigt F, Maass N. et al. Anwendung und Dosierung von Misoprostol zur Geburtseinleitung – Deutschland 2013 und im internationalen Vergleich. Z Geburtshilfe Neonatol 2017; 218: 15
• 12 Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM). Cytotec® (Misoprostol): Risiken im Zusammenhang mit einer Anwendung zur Geburtseinleitung außerhalb der Zulassung („off-label-use“). Rote-Hand-Brief vom 16. März 2020. 2020 Accessed April 12, 2025 at: https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RHB/2020/rhb-cytotec.html
• 13 Gemeinsamer Bundesausschuss. Dossier zur Nutzenbewertung gemäß §35a SGB V. Misoprostol (Angusta®). Norgine GmbH. Modul 2. Allgemeine Angaben zum Arzneimittel und zugelassene Anwendungsgebiete. 30.08.2021 Accessed April 12, 2025 at: https://www.g-ba.de/downloads/92-975-5056/2021_08_30_Modul2_Misoprostol.pdf
• 14 Tunaru S, Althoff TF, Nüsing RM. et al. Castor oil induces laxation and uterus contraction via ricinoleic acid activating prostaglandin E 3 receptors. Proc Natl Acad Sci U S A 2012; 109: 9179-9184
• 15 Norgine GmbH. Zusammenfassung der Merkmale des Arzneimittels. Angusta 25 Mikrogramm Tabletten. 2020 Accessed April 12, 2025 at: https://www.fachinfo.de/fi/pdf/023457
• 16 Kerr RS, Kumar N, Williams MJ. et al. Low-dose oral misoprostol for induction of labour. Cochrane Database Syst Rev 2021; (06) CD014484
• 17 Henrich W, Dudenhausen JW, Hanel C. et al. Prospektiv randomisierte Studie zum Vergleich von Misoprostol oral mit Dinoproston vaginal bei der Geburtseinleitung am Termin. Z Geburtshilfe Neonatol 2008; 212: 183-188
• 18 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG). S2k-Leitlinie Peripartale Blutungen, Diagnostik und Therapie. Peripartal haemorrhage, diagnosis and therapy. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/063). 2022 Accessed April 13, 2025 at: https://register.awmf.org/de/leitlinien/detail/015-063
• 19 World Medical Association. WMA Declaration of Helsinki – Ethical principles for medical research involving human subjects. Amended by the 64th WMA General Assembly. 2013 Accessed April 13, 2025 at: https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/
• 20 Deutsche Gesellschaft für Gynäkologie und Geburtshilfe e. V. (DGGG). S2k-Leitlinie Hypertensive Erkrankungen in der Schwangerschaft (HES): Diagnostik und Therapie. Hypertensive Disorders in Pregnancy: Diagnosis and Therapy. Guideline of the German Society of Gynecology and Obstetrics (S2k-Level, AWMF Registry No. 015/018). 2024 Accessed April 13, 2025 at: https://register.awmf.org/de/leitlinien/detail/015-018
• 21 Maschke SK, Steinkasserer L, Renz D. et al. Maternal and neonatal short-term outcome after vaginal breech delivery > 36 weeks of gestation with and without MRI-based pelvimetric measurements: a Hannover retrospective cohort study. J Perinat Med 2024; 53: 316-326
• 22 Ellis JA, Brown CM, Barger B. et al. Influence of Maternal Obesity on Labor Induction: A Systematic Review and Meta-Analysis. J Midwifery Womens Health 2019; 64: 55-67
• 23 Beckwith L, Magner K, Kritzer S. et al. Prostaglandin versus mechanical dilation and the effect of maternal obesity on failure to achieve active labor: a cohort study. J Matern Fetal Neonatal Med 2017; 30: 1621-1626
• 24 Saucedo AM, Alvarez M, Macones GA. et al. Optimal misoprostol dosing among patients with a body mass index greater than 30: a randomized controlled trial. Am J Obstet Gynecol 2024; 230: 565.e1-565.e16
• 25 Carlhäll S, Källén K, Blomberg M. Maternal body mass index and duration of labor. Eur J Obstet Gynecol Reprod Biol 2013; 171: 49-53
• 26 Fyfe EM, Anderson NH, North RA. Screening for Pregnancy Endpoints (SCOPE) Consortium. et al. Risk of first-stage and second-stage cesarean delivery by maternal body mass index among nulliparous women in labor at term. Obstet Gynecol 2011; 117: 1315-1322
• 27 Kehl S, Weiss C, Dammer U. et al. Double-balloon catheter and sequential oral misoprostol versus oral misoprostol alone for induction of labour at term: a retrospective cohort study. Eur J Obstet Gynecol Reprod Biol 2016; 204: 78-82
• 28 Hofmeyr GJ, Gülmezoglu AM, Pileggi C. Vaginal misoprostol for cervical ripening and induction of labour. Cochrane Database Syst Rev 2010; (10) CD000941
• 29 Bennett KA, Butt K, Crane JM. et al. A masked randomized comparison of oral and vaginal administration of misoprostol for labor induction. Obstet Gynecol 1998; 92: 481-486
• 30 Levy R, Vaisbuch E, Furman B. et al. Induction of labor with oral misoprostol for premature rupture of membranes at term in women with unfavorable cervix: a randomized, double-blind, placebo-controlled trial. J Perinat Med 2007; 35: 126-129
• 31 Dodd JM, Crowther CA, Robinson JS. Oral misoprostol for induction of labour at term: randomised controlled trial. BMJ 2006; 332: 509-513
• 32 World Health Organization. WHO recommendations on the induction of labour. 2011 Accessed April 15, 2025 at: https://iris.who.int/bitstream/handle/10665/44531/9789241501156_eng.pdf
• 33 Bendix JM, Friis Petersen J, Andersen BR. et al. Induction of labor with high- or low-dosage oral misoprostol-A Danish descriptive retrospective cohort study 2015–16. Acta Obstet Gynecol Scand 2020; 99: 222-230
• 34 Wesselius SM, de Groot CJM, de Heus R. et al. Improved neonatal outcome following induction of labour using 25 µg versus 50 µg oral Misoprostol: A retrospective, comparative cohort study. J Gynecol Obstet Hum Reprod 2025; 54: 102927
• 35 Kehl S, Karademir ZS, Weiss C. et al. Low-dose Oral Misoprostol after Cervical Ripening with a Double-balloon Catheter: 25 µg or 50 µg?. Geburtshilfe Frauenheilkd 2025; 85: 210-218
• 36 Helmig RB, Hvidman LE. An audit of oral administration of Angusta® (misoprostol) 25 µg for induction of labor in 976 consecutive women with a singleton pregnancy in a university hospital in Denmark. Acta Obstet Gynecol Scand 2020; 99: 1396-1402
• 37 Kandahari N, Schneider AN, Tucker LS. et al. Labor Induction Outcomes with Outpatient Misoprostol for Cervical Ripening among Low-Risk Women. Am J Perinatol 2024; 41: e818-e826
• 38 Middleton P, Shepherd E, Morris J. et al. Induction of labour at or beyond 37 weeks’ gestation. Cochrane Database Syst Rev 2020; (07) CD004945
• 39 Fonseca MJ, Santos F, Afreixo V. et al. Does induction of labor at term increase the risk of cesarean section in advanced maternal age? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 253: 213-219
• 40 Pfleiderer M, Gilman E, Grüttner B. et al. Maternal and Perinatal Outcome After Induction of Labor Versus Expectant Management in Low-risk Pregnancies Beyond Term. In Vivo 2024; 38: 299-307
• 41 Amini M, Reis M, Wide-Swensson D. A Relative Bioavailability Study of Two Misoprostol Formulations Following a Single Oral or Sublingual Administration. Front Pharmacol 2020; 11: 50
• 42 Salzberger H, Maul H. Selbstherstellung von Misoprostol-Präparaten aus Kostengründen – was ist erlaubt?. Geburtshilfe Frauenheilkd 2022; 82: 685-688